Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Cipla Limited partners with ImmunoACT to launch talicabtagene autoleucel CAR-T therapy for blood cancers in South Africa, ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
Cipla partners with ImmunoACT to commercialise CAR-T cell therapy in South Africa, Algeria, and Morocco. Expanding access to innovative cancer treatment.
Cipla Limited, through its subsidiary Medpro Pharmaceutica, has entered into an exclusive license and supply agreement with ...
Funding will allow Birmingham researchers to develop new drugs to improve outcomes for children with leukaemia.
Organizers will sell raffle and 50/50 tickets at the game, with proceeds supporting Colton Strong Kids.
We hope to reach our fundraising target of £100,000 so the charity can help even more families and young people with cancer ...
DuPont will release its fourth quarter and full year 2025 financial results at 6:00 a.m. ET on Tuesday, February 10, 2026. In addition, the company will host a conference call at 8:00 a.m. ET that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results